BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27663478)

  • 21. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies.
    Ye Z; Ding Y; Chen Z; Li Z; Ma S; Xu Z; Cheng L; Wang X; Zhang X; Ding N; Zhang Q; Qian Q
    Cancer Biol Ther; 2019; 20(4):546-551. PubMed ID: 30572767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells.
    Eslami-S Z; Cortés-Hernández LE; Alix-Panabières C
    Cells; 2020 Aug; 9(8):. PubMed ID: 32764280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical utility of non-EpCAM based circulating tumor cell assays.
    Austin RG; Huang TJ; Wu M; Armstrong AJ; Zhang T
    Adv Drug Deliv Rev; 2018 Feb; 125():132-142. PubMed ID: 29366804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonality of circulating tumor cells in breast cancer brain metastasis patients.
    Riebensahm C; Joosse SA; Mohme M; Hanssen A; Matschke J; Goy Y; Witzel I; Lamszus K; Kropidlowski J; Petersen C; Kolb-Kokocinski A; Sauer S; Borgmann K; Glatzel M; Müller V; Westphal M; Riethdorf S; Pantel K; Wikman H
    Breast Cancer Res; 2019 Sep; 21(1):101. PubMed ID: 31481116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles.
    Wang G; Benasutti H; Jones JF; Shi G; Benchimol M; Pingle S; Kesari S; Yeh Y; Hsieh LE; Liu YT; Elias A; Simberg D
    Colloids Surf B Biointerfaces; 2018 Jan; 161():200-209. PubMed ID: 29080504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a Biomarker.
    Zhang X; Li H; Yu X; Li S; Lei Z; Li C; Zhang Q; Han Q; Li Y; Zhang K; Wang Y; Liu C; Mao Y; Wang X; Irwin DM; Guo H; Niu G; Tan H
    Cell Physiol Biochem; 2018; 48(5):1983-1994. PubMed ID: 30092594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumor cells: a multifunctional biomarker.
    Yap TA; Lorente D; Omlin A; Olmos D; de Bono JS
    Clin Cancer Res; 2014 May; 20(10):2553-68. PubMed ID: 24831278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EpCAM-expressing circulating tumor cells in colorectal cancer.
    Nicolazzo C; Raimondi C; Francescangeli F; Ceccarelli S; Trenta P; Magri V; Marchese C; Zeuner A; Gradilone A; Gazzaniga P
    Int J Biol Markers; 2017 Oct; 32(4):e415-e420. PubMed ID: 28604994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'.
    Chikaishi Y; Yoneda K; Ohnaga T; Tanaka F
    Oncol Rep; 2017 Jan; 37(1):77-82. PubMed ID: 27840987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
    Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
    PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
    Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
    Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
    Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.